A Phase 1/2 interventional study of mRNA-1189 and Placebo in Epstein-Barr Virus Infection, sponsored by ModernaTX, Inc.. Active, not recruiting at 65 sites in United States. Open to participants aged 10 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Epstein-Barr Virus Infections with a site in United States — 19 open to participants now, 25 under way, 2 of them phase 3. Epstein-Barr Virus Infections · United States.
Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, this one is the 4th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2021, is one of 19 in phase 1/2, reaches primary completion later than 2 of the 23 other live ones, and was the 61st registered.
175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.
Browse Epstein-Barr Virus Infections studies →19 of the 76 studies in Epstein-Barr Virus Infections with a site in United States are open now. Recruiting first, the newest first:
Pierluigi Porcu · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–29 · Healthy volunteers
Jessie L. Alexander · Sites in United States
Ages 1 mo–65 yrs
Monica Bhatia · Sites in United States
Ages 3 mo–26 yrs
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.
This study: 10 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 40 · Phase 3 5
First in 1976; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 867 is above the median of 28 across 114 interventional studies indexed under Epstein-Barr Virus Infections.
Median enrollment 25 across the 63 interventional studies, 160 across the 11 observational. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Moderna, Inc. has 3 studies filed under Epstein-Barr Virus Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Epstein-Barr Virus Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03266653New York Medical CollegeEBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | 2026-12-31 |
| NCT02048332Children's Hospital Medical Center, CincinnatiDonor-Derived Viral Specific T-cells (VSTs) | 2027-01 |
| NCT04013802Baylor College of MedicineTETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. | 2027-05-01 |
| NCT04554914Pierre Fabre MedicamentA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | 2027-06 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A: Healthy adult from 18 to 30 years of age (inclusive) at the time of consent (Screening Visit, Day 0).
Part B:
Healthy baseline EBV-seronegative adolescents from 12 to \<18 years of age at the time of consent (Screening Visit, Day 0).
Part C:
Healthy adolescents and adults from 10 to 21 years of age (inclusive) at the time of consent (Screening Visit, Day 0).
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
Biological: Placebo
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
Biological: Placebo
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
Biological: mRNA-1189
Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
Biological: Placebo
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time frame: Up to Day 176 (7-day follow-up after vaccination)
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Up to Day 197 (28-day follow-up after vaccination)
Number of Participants with SAEs, MAAEs, Any AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine and AEs of Special Interest (AESIs)
Time frame: Day 1 to end of study (EOS) (Day 505)
Number of Participants with Laboratory Abnormalities
Time frame: Up to Day 176 (7-day follow-up after vaccination)
Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb)
Time frame: Days 1, 85, and 197
Geometric Mean Concentration (GMC) of Antigen-specific Binding Antibody (bAb)
Time frame: Days 1, 85, and 197
Geometric Mean Fold Rise (GMFR) of B-Cell nAb and Antigen-specific bAb
Time frame: Days 1, 85, and 197
Number of Participants with Seroresponse of B-Cell nAbs and Antigen-specific bAbs
The number of participants with seroresponse for EBV-specific (vaccine antigen) binding and nAbs responses and with \>2-, 3-, and 4-fold increases in serum binding or nAb titers from baseline will be analyzed with 2-sided 95% CI using the Clopper-Pearson method by treatment arm and baseline EBV serostatus, and timepoint.
Time frame: Days 1, 85, and 197
Started Dec 2021 (actual). Primary completion is estimated for Oct 2026, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epstein-Barr Virus Infections →